Next-generation synthetic cellular controls
The problem
The advancement of next-generation cell therapies is limited by manufacturing costs and the availability of live cell standards.
The solution
Synthetic cells that can accurately mimic the properties of live cells in cell manufacturing and diagnostics applications.
Our engagement
Anterra participated in the Series A round alongside Northpond Ventures and Arch Ventures.
Our other companies
Food marketplace helping people eat better effortlessly
Digital procurement platform for farm inputs and services
Innovative materials to extend fresh produce shelf life
Real-time data collection tools for farm machinery
Financial and data services for the fresh produce industry
Drug discovery using machine learning
Genome engineering using CRSPR-Cas9
Novel flavor generation using modified brewer’s yeast
Plant-based enteral nutrition products
Microbiome innovation for animal health